



Contact:

Torre St. Saviour

Dilon Diagnostics

C: 757-897-7115

O: 757-269-4910 x 312

E: tstsaviour@dilon.com

www.dilon.com

**Dilon Diagnostics to Launch Acella System for Molecular Breast Imaging
This Week at the Society of Nuclear Medicine Meeting**

Newport News, Va., June 1, 2011 — Dilon Diagnostics will introduce the latest advancement in molecular breast imaging (MBI) this week at the Society of Nuclear Medicine Meeting in San Antonio, Texas. The new Dilon 6800 Acella is equipped with the largest detector in the MBI industry, making Dilon Diagnostics the only MBI company to offer customers a choice in detector sizes.

MBI, also referred to as Breast-Specific Gamma Imaging (BSGI), is a functional imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms, particularly for those with dense breasts. Dilon strongly believes that providing customers with options such as a large FOV system and a biopsy guidance platform is imperative to serving the individual needs of each facility and key to personalized healthcare.

Last year, following the successful launch of Dilon's breast biopsy localization device (GammaLōc®), Dilon began the development of a larger detector. According to Robert G. Moussa, President and CEO at Dilon Diagnostics, "With the increasing need to better serve a growing population of large breasted patients, we felt it was crucial to provide a solution to help facilities reduce tiling, exam times and ultimately, continue to optimize their workflow. "With the launch of the Acella," said Moussa, "I am proud to say that customers now have that option."

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800®, is a high-resolution, small field-of-view digital gamma camera, optimized for breast imaging (MBI/BSGI). MBI utilizes radiotracer uptake to detect the increased metabolic activity of breast lesions and therefore, is not affected by breast density. Both the Dilon 6800® and Acella systems provide the high photon sensitivity needed to perform low dose MBI/BSGI studies. Dilon's GammaLōc® System is the only localization device on the market to enable gamma-guided breast biopsy. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; Lahey Clinic, Boston; George Washington University, Washington D.C. For more information on Dilon Diagnostics please visit www.dilon.com

###